Embody — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Embody is a commercial-stage medical device company specializing in regenerative medicine for orthopedic soft tissue repair. Its core technology is the TAPESTRY Biointegrative Implant, a collagen-based scaffold designed to support healing in challenging tendon and ligament procedures. The company has commercialized products for foot & ankle, shoulder (rotator cuff), and knee applications, and was acquired by Zimmer Biomet, which provides significant commercial scale and resources. Embody's mission is to advance the standard of care in soft tissue healing through its innovative, biologically-focused platform.

OrthopedicsSports Medicine

Technology Platform

Proprietary collagen-based biointegrative scaffold (TAPESTRY) designed to mimic native tissue structure and guide patient's own tissue ingrowth for soft tissue healing.

Opportunities

Leveraging Zimmer Biomet's global commercial infrastructure to rapidly scale adoption in high-volume soft tissue repair markets like rotator cuff (800k+ U.S.

procedures/year).

Expanding the TAPESTRY platform into adjacent orthopedic indications and developing next-generation, combination regenerative products within a well-resourced corporate environment.

Risk Factors

Clinical adoption depends on generating robust long-term data proving superior healing outcomes versus standard repair.

Faces intense competition in the sports medicine biologics space from both large medtech players and innovative startups.

Integration and strategic focus within a large parent company could alter original development priorities.

Competitive Landscape

Embody operates in the competitive sports medicine and orthopedic biologics market, competing with large players like Arthrex, Smith & Nephew, and Stryker, who have broad portfolios of mechanical repair devices and biologic augments. Its key differentiation is its highly structured, collagen-based scaffold designed for biointegration, competing against other extracellular matrix (ECM) products, synthetic scaffolds, and platelet-rich plasma (PRP) therapies.

More companies in Regenerative Medicine →More companies in United States →